| Phenotypic Pre-Plated Set |
13159 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2020-07 |
ASINEX has created a diverse set of molecules by applying strict physico-chemical
and structural descriptors to ensure good solubility and permeability properties.
|
|
| Asinex in GOSTAR |
1878 compounds
41742 analogues
For cherry-picking
Update: 2020-11 |
Asinex have opted to use the Global Online Structure Activity Relationship Database
(GOSTAR) as an integrated source of data capturing chemical, biological,
pharmacological, and therapeutic parameters. The structural overlap between the
Asinex (500K+) and GOSTAR (8M+) databases has revealed 17910 unique molecules with
associated biological activity. Application of additional structural filters (PAINS,
Eli Lilly [4-5]) has resulted in a set of 11923 compounds; diversity-oriented
selection supported by computational and medicinal chemistry expertise has further
refined this set resulting in 1878 molecules available for computational or in vitro
evaluation. Biological diversity is represented by multiple target families where
each molecule is associated with a GOSTAR record via a unique structure code
identifier.
|
|
SL#004
Oncology Phenotypic Screening-1
(Non-Macrocycle) |
80 compounds / set
Pre-Plated Set
Update: 2016 |
ASINEX's oncology-oriented phenotypic library includes compounds based on several
scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of
cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer),
MCF-7 (human breast adenocarcinoma), A-172 (Human glioblastoma), COLO-320
(colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant
melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229
(glioblastoma). Some active compounds were screened in a biochemical assay showing
nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR,
PDGFR.
|
|
SL#023
Oncology Phenotypic Screening-2
(Colon Cancer/Non-Macrocycle) |
80 compounds / set
Pre-Plated Set
Update: 2016 |
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116,
SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series
of related compounds that kill cancer cells at sub-µM concentrations with limited
off target effect on healthy cells (human fibroblasts). Additional screening in a
cell-based luciferase reporter assay of Wnt signaling has provided preliminary
evidence of Wnt-dependent mechanism of action.
|
|
SL#035
Oncology Phenotypic Screening-3
(Macrocycles) |
80 compounds / set
Pre-Plated Set
Update: 2016 |
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO,
HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of
peptidic and non-peptidic macrocycles and identified a series of compounds that kill
cancer cells at µM concentrations.
|
|
